Tratamiento contra el mieloma múltiple latente de alto riesgo.

OBJECTIVE: To review medical literature with the proposal of identifying promising new treatments against smoldering multiple myeloma. METHOD: A search was made in PubMed of MeSH terms about smoldering multiple myeloma. RESULTS: A total of 196 results was obtained, and after their evaluation, 8 studies were included to carry out this review. Administration of lenalidomide, lenalidomidedexamethasone, or cafilzomib-lenalidomide-dexamethasone have been associated with increased disease-free survival time, or progression to a clonal phase. CONCLUSIONS: To date, administration of lenalidomide or lenalidomide-dexamethasone is suggested as a promising treatment to stop the progression of smoldering multiple myeloma. However, there is no clinical practice guideline to suggest its use yet, so it is recommended that more high-quality clinical trials be conducted in the future with focus on its utility to treat this relatively novel disease. [ABSTRACT FROM AUTHOR]